Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

Funding Opportunity PAR-22-185 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatitis B, Hepatitis C and Tuberculosis).
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding